| 10.87 0.01 (0.09%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.71 | 1-year : | 14.85 |
| Resists | First : | 10.89 | Second : | 12.71 |
| Pivot price | 10.87 |
|||
| Supports | First : | 10.83 |
Second : | 10.8 |
| MAs | MA(5) : | 10.86 |
MA(20) : | 10.86 |
| MA(100) : | 10.72 |
MA(250) : | 10.55 |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 66.6 |
D(3) : | 61.9 |
| RSI | RSI(14): 63.4 | |||
| 52-week | High : | 10.89 | Low : | 10.28 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DMAA ] has closed above bottom band by 49.0%. Bollinger Bands are 3.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.9 - 10.96 | 10.96 - 11.01 |
| Low: | 10.72 - 10.79 | 10.79 - 10.84 |
| Close: | 10.76 - 10.87 | 10.87 - 10.97 |
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
Wed, 14 Oct 2026
Drugs Made In America Acquisition (DMAA) Stock Price, News & Analysis - Stock Titan
Tue, 15 Sep 2026
Drugs Made In America Restructures Merger with PAGC - The Globe and Mail
Tue, 08 Sep 2026
DMAA resets Power Analytics merger at $2.85B fixed valuation - Dealroom
Thu, 13 Aug 2026
Mizuho Financial Group (DMAA) discloses 8.5% beneficial stake in SPAC - Stock Titan
Wed, 08 Apr 2026
Drugs Made in America Acquisition Corp. signs LOI for de-SPAC with Power Analytics - Investing.com
Thu, 25 Sep 2025
Drugs Made In America Acquisition II prices $500 million IPO at $10 per unit - Investing.com UK
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Shell Companies
|
|
| Shares Out | 24 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 23.5 (%) |
| Held by Institutions | 53.4 (%) |
| Shares Short | 90 (K) |
| Shares Short P.Month | 79 (K) |
| EPS | 0.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.32 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -17.9 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 60.38 |
| PEG Ratio | 0 |
| Price to Book value | -35.07 |
| Price to Sales | 0 |
| Price to Cash Flow | -510.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|